Albireo AB Company Profile

10:17 EST 16th December 2018 | BioPortfolio

Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfill unmet medical needs in the gastrointestinal (GI) area. The Albireo team has a broad experience in drug development, primarily in the GI area and has an extensive network in the international scientific and clinical communities. Albireo was created as a spin out of AstraZeneca and was based on a platform of clinical and preclinical GI programs emanating from within AstraZeneca. Albireo has raised $40m in a Series A financing round from leading healthcare investors including Nomura Phase4 ventures, TPG Biotech, TVM Capital and Scottish Widows Partnership.

News Articles [37 Associated News Articles listed on BioPortfolio]

FDA fast-tracks Albireo's rare liver disease therapy

Albireo Pharma's late-stage A4250, developed to treat patients with progressive familial intrahepatic cholestasis, was grant -More- 

Orphan Tech’s Patrick Horn Joins Albireo as Chief Medical Officer

Albireo Pharma (NASDAQ: ALBO) has appointed Patrick Horn to serve as chief medical officer. He will succeed Paresh Soni, who is stepping down from the Boston company but will continue to serve as a co...

FDA grants rare pediatric disease status to Albireo's liver disease drug

Albireo Pharma's late-stage candidate A4250 was given rare pediatric disease status by the FDA.  -More- 

FDA Grants Rare Pediatric Disease Designation to Albireo’s Liver Disease Drug

The U.S. Food and Drug Administration (FDA) granted Boston-based Albireo Pharma’s A4250 rare pediatric disease designation.

Albireo gets FDA rare pediatric disease designation for rare liver disease treatment A4250

Albireo Pharma has secured rare pediatric disease designation from the US Food and Drug Administration for its product candidate, A4250, to treat progressive familial intrahepatic cholestasis (PFIC).

FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher

Albireo Pharma (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the U.S. Food and Drug Administration (FDA) has granted rar...

Albireo Pharma advancing its pipeline to treat pediatric liver disease

Albireo Pharma Inc (NASDAQ:ALBO) CEO Ron Cooper tells Proactive Investors the Boston-based biopharma started a Phase 3 trial for its drug A4250 in May, aiming to treat progressive familial intrahepa...

Management tracks: Ionis, Albireo

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]

Albireo AB

Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfill unmet medical needs in the gastrointestinal (GI) area. The Albir...

More Information about "Albireo AB" on BioPortfolio

We have published hundreds of Albireo AB news stories on BioPortfolio along with dozens of Albireo AB Clinical Trials and PubMed Articles about Albireo AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Albireo AB Companies in our database. You can also find out about relevant Albireo AB Drugs and Medications on this site too.

Quick Search


Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Corporate Database Quicklinks

Searches Linking to this Company Record